ADVERTISEMENT
Biocon Q4 Result Review: Competition May Mire Down Potential Turnaround, Says ICICI Securities, Retains 'Sell'
In the near term, Biocon has five launches lined up, which should boost growth; however, competition challenges persist, says ICICI Securities.
12 May 2025, 05:19 PM IST 
Save
%20Syngene%20is%20a%20subsidiary%20of%20Biocon%20Ltd..jpg?rect=1%2C0%2C3870%2C2177&auto=format%2Ccompress&fmt=avif&mode=crop&ar=16%3A9&q=60)
Biocon's revenue, in Q4 FY25, grew 12.8% YoY (+15.6% QoQ) to Rs 44.2 billion driven by an outperformance in the generic segment. (Photo source: Biocon website)
Inventory channel filing of gRevlimid in US was a key reason for the outperformance in Q4 FY25; besides, performance of other segments was in-line with our expectations. Ahead, Biocon has lined up five new biosimilars, which should help the company to reduce its revenue concentration (top-4 biologics account for 75% of biologic sales in FY25) and improve gross and Ebitda margins in the next couple of years.
